Gap Inc V.GAP

Interesting article on Ovarian Ca spread

[andyro]

Recently came across an interesting article on Ovarian Cancer that got me thinking on the previous NR from PGAP in April 2011 that showed GAP-107B8 “significantly suppress ascites formation (73%) relative to controls”. I believe this was done with the non-enhanced version and now the enhanced version is being tested again at OHRI in the coming weeks.


Dr. Vanderhyden had commented in the NR from April that "The reduction in ascites volume is very interesting in its own right, because this is a notable cause of morbidity in women with ovarian cancer. There is currently no drug therapy that is effective against ovarian cancer-associated ascites accumulation”. (https://www.marketwire.com/press-release/pharmagap-sees-positive-results-from-in-vivo-ovarian-cancer-models-ottawa-hospital-research-tsx-venture-gap-1503344.htm)

The below article is not about GAP-107B8 but it was interesting to learn about how Ovarian Ca spreads and then wonder if the fact that the non-enhanced version worked that well on Ascites previously what the new testing with enhanced, liposomal formulations will be.

“In 80 percent of women, by the time ovarian cancer is diagnosed, it has spread to the pad offat cells, called the omentum. Often,cancer growthin the omentum exceeds the growth of the original ovarian cancer. "Thisfatty tissue, which is extraordinarily rich in energy-dense lipids, acts as a launching pad and energy source for the likely lethal spread of ovarian cancer," said study author Ernst Lengyel, MD, PhD, professor ofobstetrics and gynecologyat the University of Chicago. "The cells that make up the omentum contain the biological equivalent of jet fuel. They feed the cancer cells, enabling them to multiply rapidly. Gaining a better understanding of this process could help us learn how to disrupt it."

https://medicalxpress.com/news/2011-10-fat-cells-abdomen-fuel-ovarian.html
Next 2 months should be very interesting!
GLTA,
Andyro